CLAIMS

1. An ~~preventive and/or therapeutic agent~~ IL-6 inhibitor for use in the treatment of retinal inflammation~~, wherein said preventive and/or therapeutic agent comprises an IL-6 inhibitor as an active ingredient~~.

2. The ~~preventive and/or therapeutic agent~~ IL-6 inhibitor for use according to claim **1**, wherein said retinal inflammation comprises atrophic age-related macular degeneration and retinitis pigmentosa.

3. The ~~preventive and/or therapeutic agent~~ IL-6 inhibitor for use according to claims **1** or **2**, wherein said IL-6 inhibitor comprises (i) an antagonist of IL-6 activity, such as an antibody recognizing IL-6, a soluble IL-6 receptor or an inhibitor of IL-6 translation or (ii) an antagonist of IL-6 receptor, such as an antibody recognizing IL-6R or an IL-6R binding peptide.

4. The ~~preventive and/or therapeutic agent~~ IL-6 inhibitor for use according to any of claims **1** to **3**, wherein said IL-6 inhibitor ~~preventive and/or therapeutic agent~~ is administered intraocularly, preferably by intravitreal injection, or applied by topical ocular administration.

5. The ~~preventive and/or therapeutic agent~~ IL-6 inhibitor for use according to any of claims **1** to **4**, wherein said ~~agent comprises an~~ IL-6 inhibitor is in a concentration from 5mg/mL to 500mg/mL.

6. Use of an IL-6 inhibitor in the manufacture of a medicament for the treatment of retinal inflammation.

7. The use of claim 6, wherein said retinal inflammation comprises atrophic age-related macular degeneration and retinitis pigmentosa.

8. The use of claims 6 and 7, wherein said IL-6 inhibitor comprises (i) an antagonist of IL-6 activity, such as an antibody recognizing IL-6, a soluble IL-6 receptor or an inhibitor of IL-6 translation or (ii) an antagonist of IL-6 receptor, such as an antibody recognizing IL-6R or an IL-6R binding peptide.

9. The use according to any of claims 6 to 8, wherein said IL-6 inhibitor is for intraocular administration, preferably by intravitreal injection, or for applications by topical ocular administration.

10. The use according to any of claims 6 to 9, wherein said IL-6 inhibitor is in a concentration from 5mg/mL to 500mg/mL.